Recent news on Panretin

Eisai buy cancer antibody specialists  -  Mar 23, 2007
LabTechnologist.com,...cancer-related products from Ligand Pharmaceuticals last October: Ontak (denileukin), Panretin (alitretinoin) gel and Targretin (bexarotene) capsules

Eisai acquires US oncology expert Morphotek for $325 million  -  Mar 23, 2007
Pharma Times (subscription),They were Ontak (denileukin diftitox) and Targretin (bexarotene) capsules and gel for T cell lymphoma, and Panretin (alitretinoin) gel, used to treat the

Eisai Taking Over Morphotek; $325M For Antibody Foothold  -  Mar 22, 2007
BioWorld Online,Targretin (bexarotene) gel and capsules, also for CTCL; and Panretin (alitretinoin) gel for Kaposi's sarcoma, an AIDS-related skin cancer.

Ligand Pharmaceuticals Announces Fourth Quarter Results  -  Mar 16, 2007
PharmaLive.com (press release),...drugs ONTAK(R) (denileukin diftitox), Targretin(R) (bexarotene) capsules, Targretin(R) (bexarotene) gel 1% and Panretin(R) (alitretinoin) gel 0.1%.

Ligand Pharmaceuticals Announces Fourth Quarter Results  -  Mar 15, 2007
Business Wire (press release),...oncology drugs ONTAK® (denileukin diftitox), Targretin® (bexarotene) capsules, Targretin® (bexarotene) gel 1% and Panretin® (alitretinoin) gel 0.1%.

Eisai Announces Completion of Acquisition of Four Oncology-Related ...  Oct 25, 2006
...exclusive global rights to ONTAK(R) (denileukin diftitox), Targretin(R) (bexarotene) capsules, Targretin(R) (bexarotene) gel 1% and Panretin(R) (alitretinoin ... -PR Newswire (press release), Ligand Completes Sale of Oncology Product Lines  Oct 25, 2006
...marketed oncology drugs: ONTAK® (denileukin diftitox), Targretin® (bexarotene) capsules, Targretin® (bexarotene) gel 1% and Panretin ® (alitretinoin) gel ... -Business Wire (press release), Ligand Announces Sale of Oncology Product Lines As Next Step in ...  Sep 7, 2006
...(New Jersey) ("Eisai"). The sale includes Ligand's four marketed oncology drugs: ONTAK, Targretin capsules, Targretin gel and Panretin gel. ... -International News Service

Ligand to Sell Oncology Line to Eisai  Sep 8, 2006
...convulsions. The sale includes Ligand's four marketed oncology drugs _ Ontak, Targretin capsules, Targretin gel and Panretin gel. ... -Houston Chronicle

Ligand Sells More Products: $205M For Cancer Portfolio  Sep 8, 2006
...involves Ontak (denileukin diftitox), for cutaneous T-cell lymphoma; Targretin (bexarotene) gel and capsules, also for CTCL; and Panretin (alitretinoin) gel ... -BioWorld Online

Eisai Acquires Four Oncology-Related Products from Ligand  Sep 8, 2006
...exclusive global rights for ONTAK® (denileukin diftitox), Targretin® (bexarotene) capsules, Targretin® (bexarotene) gel 1% and Panretin® (alitretinoin) gel ... -PipelineReview.com

Ligand Pharmaceuticals To Sell Oncology Product Line, Assets To ...  Sep 7, 2006
...(New Jersey). Ligand stated that the sale includes its four marketed oncology drugs namely ONTAK, Targretin capsules, Targretin gel and Panretin gel. ... -Trading Markets

Eisai to Acquire Global Rights to Four Oncology-Related Products ...  Sep 8, 2006
Nasdaq: LGND) for exclusive global rights for their four oncology-related products, ONTAK, Targretin capsules, Targretin gel 1% and Panretin gel 0.1%. ... -StreetInsider.com (subscription)

Eisai buys 4 cancer drugs from Ligand for $205 mln  Sep 8, 2006
...rare form of cancer. It will also buy Panretin gel, which is used to treat AIDS-related Kaposi's sarcoma. Under the deal, Eisai ... -Reuters

Eisai Pays $205 Million for Four Ligand Cancer Drugs (Update3)  Sep 7, 2006
The agreement also covers rights to a gel version of Targretin, and a gel version of Panretin, used to treat skin lesions in patients with AIDS-related ... -Bloomberg

BIOTECH STOCKS Drug stocks hug flat-line, King gains on Avinza ...  Sep 8, 2006
...product line to drugmaker Esai for $205 million. The sale includes the products Ontak, Targretin capsules and gel, and Panretin gel. -MarketWatch

Eisai Pays $205 Million for Four Ligand Cancer Drugs (Update1)  Sep 7, 2006
The agreement with Ligand, which is subject to government approvals, gives Eisai global rights to ONTAK, Targretin capsules, and Targretin and Panretin gels. ... -Bloomberg

Eisai Acquires Four Oncology-Related Products From Ligand  Sep 7, 2006
...exclusive global rights for ONTAK(R) (denileukin diftitox), Targretin(R) (bexarotene) capsules, Targretin(R) (bexarotene) gel 1% and Panretin(R) (alitretinoin ... -International News Service

UPDATE: Sales Reshape Ligand  Sep 8, 2006
...receive the rights to four oncology drugs — Ontak, Targretin capsules, Targretin gel and Panretin gel — and all related intellectual property, licenses ... -San Diego Business Journal

Ligand Announces Financial Results for Second Quarter of Fiscal ...  Aug 9, 2006
...this release. AVINZA, Targretin, ONTAK and Panretin are registered trademarks of Ligand Pharmaceuticals Incorporated. Each other ... -PharmaLive.com



Ligand Announces Financial Results for First Quarter of Fiscal ...  May 15, 2006
...this release. AVINZA, Targretin, ONTAK and Panretin are registered trademarks of Ligand Pharmaceuticals Incorporated. Each other ... - Genetic Engineering News





Ligand Announces Preliminary Unaudited Financial Results for 2005  Mar 16, 2006
...this release. AVINZA, Targretin, ONTAK and Panretin(R) are registered trademarks of Ligand Pharmaceuticals Incorporated. Each other ... - Genetic Engineering News

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional